MDS
the therapeutic option that improves symptoms and QOL
what is supportive care
type of AML that is caused by genetic predisposition
what is primary AML
population that is most likely to acquire ALL
what is younger individuals
vincristine
what is vinca alkaloid
only possible cure for leukemia
what is stem cell transplant
the treatment used for low risk patients with a Del(5q)
what is lenalidomide
a distinguishing symptom of AML that is not seen in other leukemias
what is chloromas
maintenance therapy for ALL should be continued for a duration of
azacitadine
what is hypomethylating agent
never give a vinca alkaloid via this route
what is intrathecally
supportive care for a patient starting lenalidomide
what is VTE prophylaxis
first line intensive treatment in patients of all ages
what is cytarabine + idarubicin/daunorubicin (7+3) +/- gemtuzumab ozogamacin
key chemotherapy agents in the first line therapy for ALL
what is anthracycline, steroid, vincristine, +/- pagaspargase
cytarabine
what is antimetabolite (pyrimidine analog)
the goal of induction phase
what is to induce remission
the length of time before a response is seen in a patient on a hypomethylating agent
what is 4-6 months
if these side effects of cytarabine occur, the medication should be discontinued because they may be irreversible
what is cerebellar side effects (dizziness, slurred speech, confusion)
required for high dose therapy of methotrexate
what is leucovorin or glucarpidase rescue
venetoclax
what is BCL-2 inhibitor
there is a potential for MDS to evolve into
what is AML
the role of erythropoiesis-stimulating agents in low risk patients with low sEPO
what is to reduce symptoms of anemia and allow for transfusion independence
medication used in AML with an IDH1 mutation
what is ivosidenib
risk stratification for a patient that is 40 years old and has a WBC count of 35,000
what is intermediate
gemtuzumab ozogamacin
what is anti-CD33
black box warning of arsenic trioxide